Search research articles

Search research articles

Related Experiment Videos

Future directions for temozolomide therapy.

¹Department of Neuro-Oncology, University of Texas, M. D. Anderson Cancer Center, Houston, TX 77030, USA.

Seminars in Oncology

|September 11, 2001

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Success rate of induction of labour in twin pregnancies relative to singleton pregnancies in a predominantly Chinese population.

Hong Kong medical journal = Xianggang yi xue za zhi·2025

Same author

A brief group intervention using a cognitive-behavioural approach to reduce postnatal depressive symptoms: a randomised controlled trial.

Hong Kong medical journal = Xianggang yi xue za zhi·2016

Same author

Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas.

Oncotarget·2016

Same author

A phase II study of bevacizumab and erlotinib after radiation and temozolomide in MGMT unmethylated GBM patients.

Journal of neuro-oncology·2015

Same author

Social obstetrics: non-local expectant mothers admitted through accident and emergency department in a public hospital in Hong Kong.

Hong Kong medical journal = Xianggang yi xue za zhi·2014

Same author

The somatic genomic landscape of glioblastoma.

Cell·2013

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Temozolomide is initially used for difficult brain cancers. Ongoing trials explore its effectiveness in various new cancers, dosing schedules, and combinations with other therapies.

Area of Science:

Oncology
Neuro-oncology
Pharmacology

Background:

Temozolomide (TMZ) is an oral alkylating agent.
Currently indicated for refractory central nervous system (CNS) malignancies like anaplastic astrocytoma and glioblastoma multiforme.
Schering Corporation developed TMZ (Temodar/Temodal).

Purpose of the Study:

To evaluate the efficacy and safety of temozolomide in new indications.
To explore modifications in temozolomide dosing and administration.
To investigate combination therapies involving temozolomide.

Main Methods:

Clinical trials are planned or ongoing.
Studies include newly diagnosed glioma, oligodendroglioma, pediatric glioma, brain metastases, and metastatic melanoma.

Related Experiment Videos

Research also covers other systemic tumors.

Main Results:

Temozolomide shows potential utility across a variety of cancers.
Ongoing research is assessing safety and efficacy in diverse patient populations and tumor types.
Investigational studies are exploring optimized treatment regimens.

Conclusions:

Temozolomide demonstrates broad therapeutic potential beyond its current indications.
Further research is warranted to establish optimal use in various oncological settings.
Temozolomide may become a valuable agent in systemic cancer treatment.